# A bone marrow niche on a chip to study human dormancy

Source: https://onco.cc/ideas/idea-bio2-marrow-niche-on-chip/  
OnCo record `idea-bio2-marrow-niche-on-chip` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Dormant cancer cells hide in bone marrow. A lab-built model of that hiding place would let us watch them sleep and wake, and test drugs on them.

## Summary

Microfluidic and organ-on-chip systems can now sustain human haematopoietic niches with mesenchymal stroma, osteoblasts and vasculature under flow. Adding patient-derived tumour cells creates a human dormancy model with live-cell imaging, in which awakening triggers such as inflammation, chemotherapy or niche disruption can be dialled in and quantified.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Human marrow-niche chips reproduce the entry into and exit from dormancy and rank pro-dormancy or dormancy-killing compounds concordantly with in vivo models, making them a valid first-line assay.
- Rationale: Dormancy depends on niche cell contacts and flow that plastic dishes cannot supply, which is why the field is stuck on mouse studies. Liver and gut chips have already been accepted for some regulatory-grade toxicology, so the engineering path is known.
- Proposed test: Benchmark a chip against paired in vivo data with a blinded compound set of known dormancy modulators and inactive controls; publish concordance, cost and throughput.
- Maturity: preclinical-evidence
- Actor: engineering

## Sources

- Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022): https://doi.org/10.1056/NEJMoa2200075

## Connected records

- technologies: [Functional (ex vivo) drug testing](https://onco.cc/technologies/functional-drug-testing/), [Patient-derived organoids](https://onco.cc/technologies/organoids/), [Single-cell & spatial profiling](https://onco.cc/technologies/single-cell-spatial/)
- terms: [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)
- bottlenecks: [Dormant cells and minimal residual disease](https://onco.cc/bottlenecks/b-dormancy-mrd/), [Lab models that fail to predict what happens in patients](https://onco.cc/bottlenecks/b-preclinical-models/)

---
JSON: https://onco.cc/api/v1/entities/idea-bio2-marrow-niche-on-chip.json